Septerna (NASDAQ:SEPN) Research Coverage Started at Jones Trading

Jones Trading assumed coverage on shares of Septerna (NASDAQ:SEPN) in a research note issued to investors on Tuesday morning,Benzinga reports. The firm issued a buy rating and a $43.00 price objective on the stock.

A number of other research firms have also weighed in on SEPN. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research report on Wednesday, October 8th. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 target price on shares of Septerna in a report on Friday, September 5th. HC Wainwright increased their price target on Septerna from $26.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Raymond James Financial assumed coverage on Septerna in a research report on Friday, December 19th. They set a “strong-buy” rating and a $38.00 price objective on the stock. Finally, Truist Financial initiated coverage on Septerna in a report on Monday, December 15th. They issued a “buy” rating and a $34.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Septerna currently has an average rating of “Moderate Buy” and an average target price of $33.00.

Septerna Stock Performance

Shares of SEPN opened at $29.57 on Tuesday. The stock has a 50 day moving average price of $24.23 and a 200 day moving average price of $17.40. Septerna has a one year low of $4.17 and a one year high of $30.50. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -19.58 and a beta of 3.80.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, November 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.28). Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%.The business had revenue of $21.50 million for the quarter, compared to analyst estimates of $24.50 million. On average, analysts predict that Septerna will post -7.11 earnings per share for the current year.

Insider Activity

In related news, SVP Daniel D. Long sold 3,501 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $18.06, for a total value of $63,228.06. Following the sale, the senior vice president directly owned 92,911 shares in the company, valued at approximately $1,677,972.66. The trade was a 3.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Septerna

Institutional investors have recently made changes to their positions in the stock. BVF Inc. IL lifted its holdings in shares of Septerna by 79.3% in the 1st quarter. BVF Inc. IL now owns 4,396,124 shares of the company’s stock worth $25,454,000 after acquiring an additional 1,944,100 shares during the last quarter. Driehaus Capital Management LLC raised its position in Septerna by 20.6% in the first quarter. Driehaus Capital Management LLC now owns 3,122,608 shares of the company’s stock valued at $18,080,000 after purchasing an additional 533,055 shares during the period. Vanguard Group Inc. lifted its stake in Septerna by 7.4% during the third quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock worth $28,568,000 after purchasing an additional 104,394 shares in the last quarter. Avoro Capital Advisors LLC boosted its position in shares of Septerna by 8.1% during the third quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock worth $25,158,000 after buying an additional 100,000 shares during the period. Finally, ADAR1 Capital Management LLC grew its stake in shares of Septerna by 38.9% in the third quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company’s stock valued at $22,130,000 after buying an additional 329,264 shares in the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.